keyword
MENU ▼
Read by QxMD icon Read
search

Drug pricing

keyword
https://www.readbyqxmd.com/read/28430013/barriers-to-access-to-sterile-syringes-as-perceived-by-pharmacists-and-injecting-drug-users-implications-for-harm-reduction-in-lebanon
#1
Ali Ghaddar, Karine Nassar, Ghadier Elsoury
BACKGROUND: Access to sterile syringes to injecting drug users (IDU) reduces sharing behavior and prevents the transmission of HIV. OBJECTIVES: To describe the barriers to access to sterile syringes for IDUs in Lebanon from the perspectives of pharmacists and IDUs. METHODS: in this qualitative study conducted in Lebanon, data were collected from 72 syringe purchase tests at pharmacies, 64 interviewees with pharmacists and 2 focus groups with injecting drug users...
April 21, 2017: Substance Use & Misuse
https://www.readbyqxmd.com/read/28427594/the-bioresorbable-drug-eluting-coronary%C3%A2-stent-the-price-is-right
#2
EDITORIAL
Michael A Kutcher
No abstract text is available yet for this article.
April 24, 2017: JACC. Cardiovascular Interventions
https://www.readbyqxmd.com/read/28427466/determinants-of-orphan-drugs-prices-in-france-a-regression-analysis
#3
Daria Korchagina, Aurelie Millier, Anne-Lise Vataire, Samuel Aballea, Bruno Falissard, Mondher Toumi
BACKGROUND: The introduction of the orphan drug legislation led to the increase in the number of available orphan drugs, but the access to them is often limited due to the high price. Social preferences regarding funding orphan drugs as well as the criteria taken into consideration while setting the price remain unclear. The study aimed at identifying the determinant of orphan drug prices in France using a regression analysis. METHODS: All drugs with a valid orphan designation at the moment of launch for which the price was available in France were included in the analysis...
April 21, 2017: Orphanet Journal of Rare Diseases
https://www.readbyqxmd.com/read/28426846/affordability-of-cancer-drugs-in-sub-saharan-africa-effects-of-pricing-on-needless-loss-of-life
#4
Yehoda M Martei, Agnes Binagwaho, Lawrence N Shulman
No abstract text is available yet for this article.
April 20, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28426107/controversies-and-consensus-in-the-innovation-access-for-cancer-therapy-in-the-european-countries-on-the-subject-of-metastatic-prostate-cancer
#5
S Oudard, F Courbon
Innovative cancer therapies and advances in drug development have created new hopes for patients and health providers. The purpose of this article was to evaluate the discrepancies in the assessment of the magnitude of benefit of four new drugs (abiraterone acetate, enzalutamide, cabazitaxel, radium-223 dichloride) for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The comparison was done among three European countries (UK, Germany and France) and Canada, according to the statement of each country and to the European Society of Medical Oncology (ESMO) Magnitude of Clinical Benefit Scale...
February 1, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28424972/biosimilars-in-the-united-states-emerging-issues-in-litigation
#6
REVIEW
Alice Yuen-Ting Wong, Martha M Rumore, Albert Wai-Kit Chan
Many first-generation biologics will lose their patent protection by 2020. The biosimilars market is not only attractive but also competitive and tough. The United States (US) is the world's largest pharmaceutical market and is critical to the success of most drugs. However, unclear regulatory requirements and confusing patent resolution procedures create hurdles to market entry of biosimilars. Trade secret exposure and scant exclusivity and adoption also limit the market access of biosimilars. Both biologics and biosimilar developers should closely follow the regulatory and litigation landscape to successfully navigate through the challenges...
April 19, 2017: BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
https://www.readbyqxmd.com/read/28420990/managed-entry-agreements-for-oncology-drugs-lessons-from-the-european-experience-to-inform-the-future
#7
Kim Pauwels, Isabelle Huys, Sabine Vogler, Minne Casteels, Steven Simoens
Objectives: The aim of this study is to conduct an analysis on the regulation and application of managed entry agreements (MEA) for oncology drugs across different European countries. Methods: Literature search and document analysis were performed between September 2015 and June 2016 to collect information on the regulatory framework and practice of MEA in Belgium, The Netherlands, Scotland, England and Wales, Sweden, Italy, Czech Republic and France. An overview of the content and typology of MEA applied for oncology drugs between 2008 and 2015 was generated based on publically available sources and contributions by national health authorities...
2017: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/28414846/clinical-trials-in-latin-america-implications-for-the-sustainability-and-safety-of-pharmaceutical-markets-and-the-wellbeing-of-research-subjects
#8
Núria Homedes, Antonio Ugalde
This study sought to verify whether drugs approved by the US Food and Drug Administration (FDA) were registered, commercialized and sold at affordable prices in the Latin American countries where they had been tested, as well as to ascertain their contribution to the quality of the pharmaceutical market. The list of New Molecular Entities (NMEs) approved by the FDA in 2011 and 2012 was consulted to determine the countries where pivotal trials were conducted. Affordability was assessed as a proportion of income and information on safety and efficacy was gathered from independent drug bulletins...
July 2016: Salud Colectiva
https://www.readbyqxmd.com/read/28409734/intratumoral-delivery-of-bortezomib-impact-on-survival-in-an-intracranial-glioma-tumor-model
#9
Weijun Wang, Hee-Yeon Cho, Rachel Rosenstein-Sisson, Nagore I Marín Ramos, Ryan Price, Kyle Hurth, Axel H Schönthal, Florence M Hofman, Thomas C Chen
OBJECTIVE Glioblastoma (GBM) is the most prevalent and the most aggressive of primary brain tumors. There is currently no effective treatment for this tumor. The proteasome inhibitor bortezomib is effective for a variety of tumors, but not for GBM. The authors' goal was to demonstrate that bortezomib can be effective in the orthotopic GBM murine model if the appropriate method of drug delivery is used. In this study the Alzet mini-osmotic pump was used to bring the drug directly to the tumor in the brain, circumventing the blood-brain barrier; thus making bortezomib an effective treatment for GBM...
April 14, 2017: Journal of Neurosurgery
https://www.readbyqxmd.com/read/28408000/cost-effectiveness-analysis-of-systemic-therapies-in-advanced-pancreatic-cancer-in-the-canadian-health-care-system
#10
Doug Coyle, Yoo-Joung Ko, Kathryn Coyle, Ronak Saluja, Keya Shah, Kelly Lien, Henry Lam, Kelvin K W Chan
OBJECTIVES: To assess the cost-effectiveness of gemcitabine (G), G + 5-fluorouracil, G + capecitabine, G + cisplatin, G + oxaliplatin, G + erlotinib, G + nab-paclitaxel (GnP), and FOLFIRINOX in the treatment of advanced pancreatic cancer from a Canadian public health payer's perspective, using data from a recently published Bayesian network meta-analysis. METHODS: Analysis was conducted through a three-state Markov model and used data on the progression of disease with treatment from the gemcitabine arms of randomized controlled trials combined with estimates from the network meta-analysis for the newer regimens...
April 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/28404202/hepatitis-c-treatment-as-prevention-evidence-feasibility-and-challenges
#11
REVIEW
Behzad Hajarizadeh, Jason Grebely, Marianne Martinello, Gail V Matthews, Andrew R Lloyd, Gregory J Dore
The advent of interferon-free direct-acting antiviral therapy for hepatitis C virus (HCV) infection has heightened discussion of treatment as prevention. Rapid scale-up in many settings, and the prospect of further treatment simplification have extended therapeutic optimism towards HCV elimination. However, questions remain regarding the feasability of HCV treatment as prevention, including real world efficacy of direct-acting antiviral therapy, particularly among people who inject drugs, and whether expanded treatment access will be sufficient to reduce HCV transmission...
December 2016: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28403233/cost-effectiveness-of-cetuximab-and-panitumumab-for-chemotherapy-refractory-metastatic-colorectal-cancer
#12
Adriana Camargo Carvalho, Frederico Leal, Andre Deeke Sasse
BACKGROUND: Cetuximab and panitumumab are monoclonal antibodies targeting the epidermal growth factor receptor. Both drugs are active against RAS wild type metastatic colorectal cancer after chemotherapy failure, with similar efficacy and toxicity profiles. However, their cost and limited survival benefits may compromise incorporation in the Brazilian public healthcare system, the Unified Heath System (Sistema Único de Saúde) (SUS). METHODS: A cost-effectiveness analysis was conducted using a Markov model from the Brazilian Public health perspective and a lifetime horizon in patients with RAS -wt mCRC...
2017: PloS One
https://www.readbyqxmd.com/read/28403027/candidates-for-inclusion-in-a-universal-antiretroviral-regimen-tenofovir-alafenamide
#13
Dzintars Gotham, Andrew Hill, Anton L Pozniak
PURPOSE OF REVIEW: Tenofovir disoproxil fumarate (TDF) is a standard first-line therapy for HIV. Recently, tenofovir alafenamide (TAF), a different prodrug for the same active moiety, has been approved. In this review, we have conducted a meta-analysis comparing efficacy and safety data for TDF and TAF, to inform a discussion of which drug would be best for a proposed 'universal antiretroviral (ARV) regimen'. RECENT FINDINGS: We identified 10 randomized controlled trials comparing TDF with TAF (6969 patients, 8043 patient-years of follow-up)...
April 11, 2017: Current Opinion in HIV and AIDS
https://www.readbyqxmd.com/read/28401419/the-impact-of-quality-of-life-data-in-relative-effectiveness-assessments-of-new-anti-cancer-drugs-in-european-countries
#14
Sarah Kleijnen, Teresa Leonardo Alves, Kim Meijboom, Iga Lipska, Anthonius De Boer, Hubertus G Leufkens, Wim G Goettsch
PURPOSE: The aim of this study is to investigate the role of health-related quality-of-life (QoL) data in relative effectiveness assessments (REAs) of new anti-cancer drugs across European jurisdictions, during health technology assessment procedures. METHODS: Comparative analysis of guidelines and publicly available REAs in six European jurisdictions of anti-cancer drugs approved by EMA between 2011 and 2013. RESULTS: Fourteen anti-cancer drugs were included, adding up to 79 REAs...
April 11, 2017: Quality of Life Research
https://www.readbyqxmd.com/read/28400255/association-of-authorized-generic-marketing-with-prescription-drug-spending-on-antidepressants-from-2000-to-2011
#15
Ning Cheng, Tannista Banerjee, Jingjing Qian, Richard A Hansen
OBJECTIVES: Prior research suggests that authorized generic drugs increase competition and decrease prices, but little empirical evidence supports this conclusion. This study evaluated the impact of authorized generic marketing on brand and generic prices. DESIGN: Longitudinal analysis of the household component of the Medical Expenditure Panel Survey. SETTING: Interview panels over 12 years, with a new panel each year. For each panel, 5 rounds of household interviews were conducted over 30 months...
April 8, 2017: Journal of the American Pharmacists Association: JAPhA
https://www.readbyqxmd.com/read/28398897/book-reviews-great-ormond-street-handbook-of-paediatrics-2nd-edn-edited-by-stephan-strobel-lewis-spitz-stephen-d-marks-crc-press-2016-price-%C3%A2-63-99-pp-736-isbn-9781482222791-stroke-medicine-2nd-edn-hugh-markus-anthony-pereira-geoffrey-cloud-oxford-university
#16
https://www.readbyqxmd.com/read/28398489/immunization-with-a-subunit-hepatitis-c-virus-vaccine-elicits-pan-genotypic-neutralizing-antibodies-and-intra-hepatic-t-cell-responses-in-non-human-primates
#17
Dapeng Li, Xuesong Wang, Markus von Schaewen, Wanyin Tao, Yunfang Zhang, Brigitte Heller, Gabriela Hrebikova, Qiang Deng, Qiang Sun, Alexander Ploss, Jin Zhong, Zhong Huang
Background: The global control of hepatitis C virus (HCV) infection remains a great burden, due to the high prices and potential drug resistance of the new direct-acting antivirals (DAAs) as well as the risk of reinfection in DAA-cured patients. Thus, a prophylactic vaccine for HCV is of great importance. We previously reported a single recombinant soluble E2 (sE2) vaccine produced in insect cells was able to induce broadly neutralizing antibodies (NAbs) and prevent HCV infection in mice...
April 8, 2017: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/28398332/drugmakers-accused-of-exploiting-orphan-drug-incentives-fueling-price-problem
#18
Brady Huggett
No abstract text is available yet for this article.
April 11, 2017: Nature Biotechnology
https://www.readbyqxmd.com/read/28393687/biosimilars-for-the-management-of-inflammatory-bowel-diseases-economic-considerations
#19
Laszlo Gulacsi, Marta Pentek, Fanni Rencz, Valentin Brodszky, Petra Baji, Zsuzsanna Vegh, Krisztina B Gecse, Silvio Danese, Laurent Peyrin-Biroulet, Peter L Lakatos
Biological drugs revolutionized the treatment of inflammatory bowel diseases (IBD) such as Crohn's disease and ulcerative colitis. However, not all clinically eligible patients have access to biologicals, due to significant costs and budget impact. Biosimilars are highly comparable to their originator product in terms of clinical efficacy and safety. Biosimilars are priced 15-75% lower than their reference product, which makes them a less costly alternative and is expected to offer better patients access to biologicals...
April 6, 2017: Current Medicinal Chemistry
https://www.readbyqxmd.com/read/28392910/drug-shortages-in-israel-regulatory-perspectives-challenges-and-solutions
#20
Eyal Schwartzberg, Denize Ainbinder, Alla Vishkauzan, Ronni Gamzu
BACKGROUND: Pharmaceutical drug shortages (DSs) are a global problem which presents challenges to countries around the world. Shortages of pharmaceutical products may have a direct detrimental impact on public health and patients' wellbeing by causing delayed, or even lack of, treatment. Moreover, DSs may force both patients and caregivers to use unfamiliar drugs, which could lead to medication errors. The objective of our study was to analyze DSs in Israel during the years 2013-2015, assessing their etiology and exploring the steps taken for their mitigation and prevention...
2017: Israel Journal of Health Policy Research
keyword
keyword
109177
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"